Clinical trial
A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum
NCT02318914 is registered in ClinicalTrials.gov with XOMA (US) LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum
- Lead sponsor
- XOMA (US) LLC
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- November 30, 2014
- Completion date
- February 29, 2016
- Enrollment
- 15 (actual)
- Sites
- 40
Conditions
As the registry lists them; a condition with its own page is linked.